Canonical WNT signalling determines lineage specificity in Wilms tumour

Oncogene

Volumn 28, Issue 8, 2009, Pages 1063-1075

  Fukuzawa, R ^a   Anaka, M R ^a   Weeks, R J ^a   Morison, I M ^a   Reeve, A E ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cancer stem cell; Mesenchymal stem cell; Multiplex ligation dependent probe amplification; Nephrogenic rest; WTX

Indexed keywords

BETA CATENIN; WNT PROTEIN;

ARTICLE; CONTROLLED STUDY; EPITHELIUM TUMOR; EXON; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MESENCHYMOMA; NEPHROBLASTOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

BETA CATENIN; CELL DIFFERENTIATION; CELL LINEAGE; CELL NUCLEUS; CHROMOSOMES, HUMAN, PAIR 11; EPITHELIUM; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC IMPRINTING; HUMANS; INSULIN-LIKE GROWTH FACTOR II; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MESODERM; MUTATION; NEPHRONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; WILMS TUMOR; WNT PROTEINS; WT1 PROTEINS;

EID: 61349113324     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.455     Document Type: Article

References (39)

1. Barberi T, Willis LM, Socci ND, Studer L. (2005). Derivation of multipotent mesenchymal precursors from human embryonic stem cells. PLoS Med 2: e161.
2. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M et al. (2007). Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007.
3. Beachy PA, Karhadkar SS, Berman DM. (2004). Tissue repair and stem cell renewal in carcinogenesis. Nature 432: 324-331.
4. Beckwith JB. (1998). Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet 79: 268-273.
5. Beckwith JB, Kiviat NB, Bonadio JF. (1990). Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol 10: 1-36.
6. Boccaccio C, Comoglio PM. (2006). Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6: 637-645.
7. Breslow NE, Beckwith JB, Perlman EJ, Reeve AE. (2006). Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor. Pediatr Blood Cancer 47: 260-267.
8. Bunting KD. (2002). ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 20: 11-20.
9. Clevers H. (2006). Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
10. Eberhart CG, Argani P. (2001). Wnt signaling in human development: beta-catenin nuclear translocation in fetal lung, kidney, placenta, capillaries, adrenal, and cartilage. Pediatr Dev Pathol 4: 351-357.
11. Eisen MB, Spellman PT, Brown PO, Botstein D. (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868.
12. Etheridge SL, Spencer GJ, Heath DJ, Genever PG. (2004). Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells. Stem Cells 22: 849-860.
13. Fodde R. (2003). The multiple functions of tumour suppressors: it's all in APC. Nat Cell Biol 5: 190-192.
14. Fukuzawa R, Heathcott RW, Sano M, Morison IM, Yun K, Reeve AE. (2004a). Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Pediatr Dev Pathol 7: 125-137.
15. Fukuzawa R, Breslow NE, Morison IM, Dwyer P, Kusafuka T, Kobayashi Y et al. (2004b). Epigenetic differences between Wilms' tumours in white and east-Asian children. Lancet 363: 446-451.
16. Fukuzawa R, Heathcott RW, More HE, Reeve AE. (2007). Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol 60: 1013-1016.
17. Fukuzawa R, Anaka MR, Heathcott RW, McNoe LA, Morison IM, Perlman EJ et al. (2008). Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes. J Pathol 215: 377-387.
18. Grohmann A, Tanneberger K, Alzner A, Schneikert J, Behrens J. (2007). AMER1 regulates the distribution of the tumor suppressor APC between microtubules and the plasma membrane. J Cell Sci 120: 3738-3747.
19. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. (2003). Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
20. Jenkins ZA, Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R, Pearl E et al. Germline mutations in the tumour suppressor WTX cause a sclerosing bone dysplasia but do not predispose to tumorigenesis. Nat Genet (in press).
21. Koesters R, Niggli F, von Knebel Doeberitz M, Stallmach T. (2003). Nuclear accumulation of beta-catenin protein in Wilms' tumours. J Pathol 199: 68-76.
22. Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F et al. (1999). Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 59: 3880-3882.
23. Li CM, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM et al. (2004). CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 165: 1943-1953.
24. Lindsley RC, Gill JG, Kyba M, Murphy TL, Murphy KM. (2006). Canonical Wnt signaling is required for development of embryonic stem cell-derived mesoderm. Development 133: 3787-3796.
25. Maiti S, Alam R, Amos CI, Huff V. (2000). Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res 60: 6288-6292.
26. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C et al. (2007). Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 316: 1043-1046.
27. Mishra L, Derynck R, Mishra B. (2005). Transforming growth factor-beta signaling in stem cells and cancer. Science 310: 68-71.
28. Morison IM, Becroft DM, Taniguchi T, Woods CG, Reeve AE. (1996). Somatic overgrowth associated with overexpression of insulin-like growth factor II. Nat Med 2: 311-316.
29. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA et al. (1993). Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362: 749-751.
30. Pardal R, Clarke MF, Morrison SJ. (2003). Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895-902.
31. Perotti D, Gamba B, Sardella M, Spreafico F, Terenziani M, Collini P et al. (2008). Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors. Oncogene 27: 4625-4632.
32. Ridgeway AG, Skerjanc IS. (2001). Pax3 is essential for skeletal myogenesis and the expression of Six1 and Eya2. J Biol Chem 276: 19033-19039.
33. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M et al. (2007). An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315: 642-645.
34. Ruteshouser EC, Robinson SM, Huff V. (2008). Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 47: 461-470.
35. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. (2002). Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30: e57.
36. Smyth GK. (2004). Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
37. Wang Y, Belflower RM, Dong YF, Schwarz EM, O'Keefe RJ, Drissi H. (2005). Runx1/AML1/Cbfa2 mediates onset of mesenchymal cell differentiation toward chondrogenesis. J Bone Miner Res 20: 1624-1636.
38. Zavadil J, Bottinger EP. (2005). TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24: 5764-5774.
39. Zirn B, Samans B, Wittmann S, Pietsch T, Leuschner I, Graf N et al. (2006). Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes Chromosomes Cancer 45: 565-574.